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Objective: Elevated levels of N-terminal pro–brain natriuretic peptide (NT-proBNP) are associated with cognitive impair-
ment, which might be explained by cardiovascular diseases or risk factors. The aim of this study was to investigate the
association of NT-proBNP with cognitive function and decline in older adults at high risk of cardiovascular disease.
Methods: We studied 5,205 men and women (mean age 5 75 years) who were recruited into the PROspective Study
of Pravastatin in the Elderly at Risk. All participants had pre-existing cardiovascular disease or risk factors thereof.
Four domains of cognitive function were tested at baseline and repeated during a follow-up period of 3.2 years.
Results: Participants with higher NT-proBNP (450ng/l) had worse baseline cognitive function, including reaction
time (mean difference high vs low group 5 3.07 seconds, 95% confidence interval [CI] 5 0.83 to 5.32), processing
speed (21.02 digits coded, 95% CI 5 21.65 to 20.39), and immediate memory (20.13 pictures remembered, 95%
CI 5 20.29 to 0.04). There was no significant difference in delayed memory (20.14, 95% CI 5 20.38 to 0.10) between
the NT-proBNP groups. Participants with higher NT-proBNP had a steeper cognitive decline, including reaction time
(mean annual change high vs low group 5 0.60 seconds, 95% CI 5 0.14 to 1.07), processing speed (20.15 digits
coded, 95% CI 5 20.25 to 20.05), immediate memory (20.05 pictures remembered, 95% CI 5 20.09 to 0.00), and
delayed memory (20.05 pictures remembered, 95% CI 5 20.11 to 0.01). Associations were independent of cardio-
vascular diseases and risks.
Interpretation: Higher NT-proBNP associates with worse cognitive function and steeper cognitive decline, independ-
ent of cardiovascular diseases and risks. Further studies to unravel the underlying mechanisms are warranted.
ANN NEUROL 2014;76:213–222
Higher levels of N-terminal pro–brain natriuretic pep-tide (NT-proBNP), a neurohormone produced by
cardiomyocytes in response to ventricular stretch, have
been associated with cognitive impairment.1–4 Evidence
comes from several cross-sectional studies, which show
that among community-dwelling older adults, higher
NT-proBNP levels were associated with worse cognitive
function, in particular memory.1–4 There are limited
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numbers of longitudinal studies with relatively small
sample sizes, which demonstrate that higher NT-proBNP
levels are also associated with steeper declines in Mini-
Mental State Examination (MMSE) scores and higher
incidence of dementia.5,6 A potential mechanism behind
the relationship between higher NT-proBNP levels and
cognitive function is clinical heart failure, resulting in left
ventricular dysfunction with subsequent reduced cardiac
output. It is hypothesized that reduced cardiac output
causes inadequate cerebral perfusion, leading to a higher
risk of cognitive impairment.7–9 Improvements in cogni-
tive function in patients following cardiac transplantation
suggest that impaired cardiac function might be a reversi-
ble risk factor for cognitive impairment.10,11
Recent evidence demonstrates that higher NT-
proBNP levels in older adults are strongly associated
with cardiovascular diseases and risk factors and predict
an increased risk of atrial fibrillation, stroke, transient
ischemic attack (TIA), myocardial infarction, and mortal-
ity, even in the absence of clinical heart failure.12–15 In
addition, higher NT-proBNP levels have been related to
left ventricular hypertrophy and systolic and diastolic
dysfunction in adults without clinical heart failure.16,17
The relationship of cardiovascular diseases and risk fac-
tors with cognitive impairment is well established.18,19
Hence, cognitive impairment might already be present in
asymptomatic older adults at early stages of reduced car-
diac function.
We hypothesized that elevated levels of NT-
proBNP are associated with a steeper cognitive decline in
older adults, which might be explained by cardiovascular
diseases or risk factors. Therefore, we studied the cross-
sectional and longitudinal association of NT-proBNP
with cognitive function in a cohort of older men and
women from the PROspective Study of Pravastatin in
the Elderly at Risk (PROSPER), in which all participants
had either preexisting cardiovascular disease or were at
risk of developing this condition.
Patients and Methods
Study Design
Data were obtained from PROSPER, a randomized, double-
blind, placebo-controlled trial designed to investigate the effect
of pravastatin in prevention of vascular events in older individu-
als with pre-existing cardiovascular disease or risk factors
thereof. This trial was conducted between 1997 and 2002 and
included 5,804 men and women aged 70 to 82 years who were
enrolled from 3 collaborating centers in Ireland, Scotland, and
the Netherlands. Approximately 50% of the participants had
cardiovascular disease including stable angina, intermittent clau-
dication, stroke, TIA, myocardial infarction, and/or vascular
surgery. The rest of the participants had 1 or more cardiovascu-
lar risk factor, defined as hypertension, smoking, or diabetes
mellitus. The primary outcome of the trial was the combined
endpoint of definite or suspected death from coronary heart
disease, nonfatal myocardial infarction, and fatal or nonfatal
stroke during a mean follow-up period of 3.2 years. The insti-
tutional ethics committees of the 3 collaborating centers
approved the study, and all participants gave written informed
consent.20,21
Study Participants
All participants had pre-existing cardiovascular disease or risk
factors thereof (defined as a history of hypertension, diabetes
mellitus, or current smoking). Participants with congestive heart
failure, defined as New York Heart Association (NYHA) func-
tional class III or IV, were excluded from the original PROS-
PER trial.20 No information on NYHA class I or II was
available. For the present study, we additionally excluded partic-
ipants with heart failure hospitalization during follow-up
(n 5 205).
NT-proBNP Measurements
Blood samples were taken at 6 months after follow-up in ethyl-
enediaminetetraacetic acid tubes.20 NT-proBNP was determined
using electrochemiluminescence immunoassay on a Roche
Modulator E170. A total of 394 participants had missing NT-
proBNP measurements. In line with existing literature on cutoff
values in this age group, we defined 3 groups of NT-proBNP:
low (<100 ng/l), middle (100–450 ng/l), and high NT-
proBNP (450 ng/l).1 Furthermore, these cutoff values were
chosen taking a pragmatic approach, to allow direct interpreta-
tion for clinical practice.
Cognitive Function
The MMSE was used to evaluate global cognitive function; par-
ticipants with a baseline score <24 points were not included in
PROSPER. Cognitive function was tested at baseline, at 9, 18,
and 30 months, and at the end of the study. The time point of
the measurement at the end of the study varied between 36
and 48 months; therefore, we performed the analysis with their
individually varying time point, but report the results for the
mean of these time points (at 42 months). Because PROSPER
was conducted in 3 countries with in total 2 languages (Dutch
and English), care was taken to select tests that are not sensitive
to language. Furthermore, all analyses were adjusted for coun-
try.22 Four different neuropsychological tests were used to assess
executive function, attention, and immediate and delayed mem-
ory. The Stroop Color and Word Test was used to test selective
attention and reaction time. Participants were asked to read a
color name, which was displayed in a color different from the
color actually named. The outcome parameter was the total
number of seconds to complete the test; a higher score indicates
worse performance. General cognitive speed was tested by the
Letter-Digit Coding Test. Participants had to match certain dig-
its with letters according to a provided key. The outcome vari-
able was the total number of correct entries in 60 seconds;
therefore, higher scores represents better performance. The
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Age, yr, mean (SD) 74.42 (3.04) 75.53 (3.37) 76.59 (3.40) <0.001
Female, No. [%] 850 [46.8] 1,490 [55.2] 360 [52.2] <0.001
Education, age on leaving school,
yr, mean (SD)
15.17 (2.06) 15.15 (2.06) 15.10 (2.08) 0.083
Vascular risk factors
History of hypertension, No. [%] 1,056 [58.1] 1,736 [64.3] 444 [64.4] <0.001
History of diabetes mellitus, No. [%] 245 [13.5] 245 [9.1] 57 [8.3] <0.001
History of stroke or TIA, No. [%] 189 [10.4] 301 [11.2] 85 [12.3] 0.371
History of myocardial infarction, No. [%] 120 [6.6] 369 [13.7] 177 [25.7] <0.001
History of vascular disease, No. [%] 630 [34.7] 1,246 [46.2] 393 [57.0] <0.001
Current smoker, No. [%] 536 [29.5] 667 [24.7] 175 [25.4] 0.001
Body mass index, kg/m2, mean (SD) 27.22 (4.02) 26.69 (4.21) 26.17 (4.20) <0.001
Total cholesterol, mmol/l, mean (SD) 5.68 (0.90) 5.68 (0.91) 5.70 (0.93) 0.461
Systolic blood pressure, mmHg,
mean (SD)
152.60 (20.25) 155.11 (21.75) 158.75 (23.50) <0.001
Diastolic blood pressure, mmHg,
mean (SD)
84.02 (10.95) 83.73 (11.33) 83.38 (12.01) 0.158
Pulse pressure, mmHg, mean (SD) 68.58 (0.42) 71.38 (0.35) 75.37 (0.68) <0.001
Mean arterial pressure, mmHg, mean (SD) 106.88 (0.30) 107.53 (0.25) 108.51 (0.49) 0.001
Systolic blood pressure trend, mmHg,
mean (SD)b
20.97 (7.94) 21.49 (9.60) 22.88 (12.44) <0.001
Diastolic blood pressure trend, mmHg,
mean (SD)b
21.25 (4.70) 21.52 (5.25) 21.93 (7.03) 0.001
Blood pressure lowering medication,
No. [%]
Diuretics 650 [35.8] 1,067 [39.5] 269 [39.0] <0.001
Loop 153 [8.4] 327 [12.1] 107 [15.5] <0.001
Other 497 [27.3] 740 [27.4] 162 [23.5]
Calcium channel blockers 459 [25.2] 692 [25.6] 151 [21.9] 0.125
Beta blockers 241 [13.3] 831 [30.8] 273 [39.6] <0.001
ACE inhibitors 279 [15.3] 421 [15.6] 134 [19.4] 0.031
eGFR, mean (SD) 62.77 (13.79) 59.64 (14.48) 55.54 (14.99) <0.001
aProbability values were calculated using log-transformed NT-proBNP levels for continuous variables and chi-square tests for cate-
gorical variables.
bDefined as the regression coefficient per year.
ACE 5 angiotensin-converting enzyme; eGFR 5 estimated glomerular filtration rate; NT-proBNP 5 N-terminal pro–brain natri-
uretic peptide; SD 5 standard deviation; TIA 5 transient ischemic attack.
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Picture-Word Learning Test was used to assess immediate and
delayed memory. Fifteen pictures were presented, and partici-
pants were asked to recall as many pictures as possible in 3 tri-
als. After 20 minutes, they were asked to repeat the pictures
they remembered to measure their delayed recall. Outcome
parameter was the accumulated number of correct recalled pic-
tures, immediately and after 20 minutes. Higher scores thus
indicate better performance. A detailed description of the cogni-
tive tests has been published previously.22 Because treatment
with pravastatin did not influence cognitive function during
follow-up, we included participants from both pravastatin and
placebo groups.23
Statistical Analysis
Baseline characteristics of the study participants are reported as
number (percentage) for categorical variables and mean (stand-
ard deviation) for continuous variables for each group of NT-
proBNP. Differences in categorical variables were tested by chi-
square tests. Differences in continuous variables were tested
with linear regression models. Because NT-proBNP levels were
not normally distributed, we used log-transformed NT-proBNP
levels to calculate p values for continuous variables. To investi-
gate the cross-sectional association of NT-proBNP with cogni-
tive function, we used linear regression models. Log-
transformed NT-proBNP levels were included as an independ-
ent variable; the outcome variable was the mean baseline score
on each of the 4 cognitive function tests. Linear mixed models
were used to examine the association between NT-proBNP and
cognitive decline over time. The models included log-
transformed NT-proBNP levels, time (in years), and the inter-
action term between time and log-transformed NT-proBNP
levels.
We performed our analyses in 3 steps. In the first step,
crude analyses were performed, in which we only adjusted for
cognitive test version where appropriate. In the second step, we
added the variables age, sex, education (age left school), coun-
try, and ApoE genotype to the model to investigate the poten-
tial influence of these factors on the associations (minimally
adjusted model). Furthermore, in a fully adjusted model we
also added the following potential confounders: cardiovascular
diseases and risk factors at baseline (history of cerebrovascular
and cardiovascular disease, hypertension, diabetes mellitus,
smoking status, high-density lipoprotein and low-density lipo-
protein cholesterol levels, triglycerides, systolic and diastolic
blood pressure, body mass index), statin treatment, and esti-
mated glomerular filtration rate (eGFR). Because the associa-
tions did not essentially change in various models, we present
the results of the minimally and fully adjusted models only.
To further explore the influence of cardiovascular diseases
and risk factors, additional analyses were performed in which
we stratified for history of cardiovascular diseases and risk fac-
tors. To test whether the difference between participants with
or without a history of cardiovascular disease or risk factor was
significant, we calculated a p value for interaction by using lin-
ear regression models. Furthermore, we performed additional
sensitivity analyses in which we excluded (1) participants taking
pravastatin treatment during follow-up; (2) participants with
incident stroke and/or TIA; (3) participants with incident myo-
cardial infarction; (4) participants with incident atrial fibrilla-
tion; (5) participants with vascular events, including coronary
heart disease death, nonfatal myocardial infarction, nonfatal
and fatal stroke, and/or TIA; (6) participants with NT-proBNP
of 450 ng/l; and (7) participants taking loop diuretics, beta
blockers, or angiotensin-converting enzyme (ACE) inhibitors at
baseline.
Results
Participants with heart failure hospitalization during
follow-up were excluded (n 5 205). A total of 394 partic-
ipants had missing NT-proBNP measurements, resulting
in a total number of 5,205 participants for the present
study.
Table 1 shows characteristics of participants
grouped by NT-proBNP levels. Participants with higher
NT-proBNP levels were older and had a higher preva-
lence of hypertension, myocardial infarction, vascular dis-
ease, and smoking (all p< 0.001). Body mass index was
lower in participants with higher NT-proBNP levels (p-
value <0.001). Systolic blood pressure, pulse pressure,
and mean arterial blood pressure were higher among par-
ticipants with higher NT-proBNP levels (p< 0.001,
p< 0.001, and p 5 0.001, respectively). Furthermore,
participants with higher NT-proBNP levels had a steeper
decline in systolic and diastolic blood pressure during
follow-up (p< 0.001 and p 5 0.001, respectively). Use of
loop diuretics, beta blockers, and ACE inhibitors was
higher in participants with higher NT-proBNP levels
(p< 0.001, p< 0.001, and p 5 0.031, respectively). Par-
ticipants with higher NT-proBNP levels had lower eGFR
(p< 0.001).
Table 2 shows the association of NT-proBNP levels
with cognitive function at baseline. In the minimally
adjusted model, participants with higher NT-proBNP
levels had worse performance on the Stroop test
(p 5 0.003) and the Letter-Digit Coding Test
(p< 0.001). The same trend was observed for immediate
and delayed Picture-Word Learning Test, showing that
participants with higher NT-proBNP levels had worse
performance, albeit these associations were not significant
(p 5 0.060 and p 5 0.066, respectively). When further
adjusting for prevalent cardiovascular diseases or risk fac-
tors at baseline, the estimates of the difference in cogni-
tive function between the groups remained essentially the
same. The association of NT-proBNP levels with the
Stroop test and Letter-Digit Coding Test in the fully
adjusted model remained significant (p 5 0.003 and
p< 0.001, respectively), whereas for immediate and
delayed Picture-Word Learning Test the associations were
ANNALS of Neurology
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not significant (p 5 0.091 and p 5 0.062, respectively).
Data on the association of NT-proBNP with cognitive
function from crude models did not materially differ
from minimally and fully adjusted models (data not
shown).
Table 3 and Figure 1 show the association of NT-
proBNP levels with changes in cognitive function during
a mean follow-up period of 3.2 years. Participants with
higher NT-proBNP levels had a steeper cognitive decline
on the Stroop test, Letter-Digit Coding Test, and imme-
diate and delayed Picture-Word Learning Test (all
p 0.001). Again, further adjustments for prevalent car-
diovascular diseases or risk factors at baseline did not
appreciably alter the observed associations (all p 0.001).
The association of NT-proBNP levels with cognitive
decline from crude models did not materially differ from
adjusted models (data not shown).
To further explore the influence of cardiovascular
diseases and risk factors, we performed additional analy-
ses in which we stratified for history of various cardiovas-
cular diseases and risk factors, and tested for interaction.
Figure 2 shows the association of NT-proBNP levels with
cognitive decline, stratified by history of cardiovascular
diseases and risk factors. There was no significant differ-
ence in change in cognitive function during follow-up
between participants with and without cardiovascular dis-
eases or risk factors, except on the Letter-Digit Coding
Test for participants with a history of stroke and/or TIA
and myocardial infarction. Participants with previous
stroke and/or TIA had a less steep decline on the Letter-
Digit Coding Test (p for interaction 5 0.003), whereas
participants with previous myocardial infarction had a
steeper decline on the Letter-Digit Coding Test (p for
interaction 5 0.008). However, no such differences were
observed for participants with previous stroke and/or
TIA or myocardial infarction on any of the other cogni-
tive tests.
Furthermore, we performed additional sensitivity
analyses to investigate whether the association between
NT-proBNP levels and cognitive function and decline
could be affected by (1) participants taking pravastatin
treatment during follow-up (n 5 2,588); (2) participants
with incident stroke and/or TIA during follow-up
(n 5 355); (3) participants with incident myocardial
TABLE 2. Association of NT-proBNP with Baseline Cognitive Function
NT-proBNP
Cognitive Tests Low, n 5 1,818,
<100 ng/l
Middle, n 5 2,698,
100–450 ng/l




Minimally adjusted model 64.37 (1.46) 64.15 (1.42) 67.40 (1.63) 0.003
Fully adjusted model 66.23 (1.56) 66.09 (1.53) 69.30 (1.72) 0.003
LDCT, digits coded
Minimally adjusted model 23.94 (0.41) 23.54 (0.40) 23.02 (0.46) <0.001
Fully adjusted model 23.33 (0.44) 22.88 (0.43) 22.31 (0.48) <0.001
PLTi, pictures remembered
Minimally adjusted model 9.58 (0.11) 9.52 (0.11) 9.44 (0.12) 0.060
Fully adjusted model 9.49 (0.12) 9.44 (0.12) 9.37 (0.13) 0.091
PLTd, pictures remembered
Minimally adjusted model 10.43 (0.16) 10.40 (0.15) 10.29 (0.17) 0.066
Fully adjusted model 10.22 (0.17) 10.19 (0.16) 10.08 (0.18) 0.062
Data represent mean (standard error) score of each cognitive function test.
Minimally adjusted model: adjusted for age, sex, country, education (age on leaving school), ApoE genotype, treatment group, and
test version for LDCT and PLT.
Fully adjusted model: minimally adjusted model 1 adjustments for history of cerebrovascular and cardiovascular disease, history of
hypertension, history of diabetes mellitus, current smoking, baseline systolic and diastolic blood pressure, high-density lipoprotein
and low-density lipoprotein cholesterol, triglycerides, body mass index, and estimated glomerular filtration rate.
aProbability values were calculated using the continuous value of log-transformed NT-proBNP levels.
LDCT 5 Letter-Digit Coding Test; NT-proBNP 5 N-terminal pro–brain natriuretic peptide; PLTd 5 Picture-Word Learning Test,
delayed; PLTi 5 Picture-Word Learning Test, immediate.
Wijsman et al: proBNP and Cognitive Decline
August 2014 217
infarction during follow-up (n 5 339); (4) participants
with incident atrial fibrillation during follow-up
(n 5 421); (5) participants with vascular events, including
coronary heart disease death, nonfatal myocardial infarc-
tion, nonfatal and fatal stroke, and/or TIA during
follow-up (n 5 648); (6) participants with NT-proBNP
levels of 450 ng/l; and (7) participants taking loop diu-
retics (n 5 588), beta blockers (n 5 1,345), or ACE
inhibitors (n 5 834) at baseline. Exclusion of these par-
ticipants did not essentially change our results (data avail-
able on request).
Discussion
In this prospective cohort study including >5,000 men
and women with a mean age of 75 years, we showed
that participants with higher NT-proBNP levels had
worse cognitive function and steeper cognitive decline
during a mean period of 3.2 years. These associations
were independent of cardiovascular diseases and risk
factors.
Our findings are in line with previous cross-
sectional studies showing that higher NT-proBNP levels
were associated with worse memory and with lower
global and executive cognitive function.1–4 Only a few
longitudinal studies with a limited number of partici-
pants investigated the association between NT-proBNP
and cognition during follow-up. They showed that
higher NT-proBNP levels are associated with a steeper
decline in MMSE scores and a higher incidence of
dementia during a mean follow-up period of 5 years.5,6
To our knowledge, this is the first study reporting on the
association of NT-proBNP and cognitive function and
decline, using an extended standardized test battery over
a mean follow-up period of 3.2 years, in a large cohort
of older adults with pre-existing cardiovascular disease or
risk factors therefor.
Brain natriuretic peptide (BNP) and the biologi-
cally inactive N-terminal proBNP are secreted by the
ventricles of the heart in response to excessive stretching
of cardiomyocytes.24 BNP has favorable physiological
properties, including increased natriuresis and diuresis,
relaxation of vascular smooth muscle cells, and inhibition
of the renin–angiotensin–aldosterone axis, eventually
causing a reduction in blood pressure and ventricular
TABLE 3. Association of NT-proBNP with Cognitive Decline during Follow-up
NT-proBNP
Cognitive Tests Low, n 5 1,818,
<100 ng/l
Middle, n 5 2,698,
100–450 ng/l




Minimally adjusted model 0.46 (0.11) 0.71 (0.09) 1.04 (0.26) 0.001
Fully adjusted model 0.47 (0.11) 0.72 (0.09) 1.04 (0.26) 0.001
LDCT, digits coded
Minimally adjusted model 20.32 (0.02) 20.36 (0.02) 20.46 (0.04) 0.001
Fully adjusted model 20.32 (0.02) 20.35 (0.02) 20.47 (0.04) <0.001
PLTi, pictures remembered
Minimally adjusted model 20.00 (0.01) 20.03 (0.01) 20.05 (0.02) <0.001
Fully adjusted model 0.00 (0.01) 20.02 (0.01) 20.04 (0.02) <0.001
PLTd, pictures remembered
Minimally adjusted model 20.05 (0.01) 20.06 (0.01) 20.10 (0.03) 0.001
Fully adjusted model 20.03 (0.01) 20.05 (0.01) 20.10 (0.03) 0.001
Data represent mean annual change (standard error) in each cognitive function test.
Minimally adjusted model: adjusted for age, sex, country, education (age on leaving school), ApoE genotype, treatment group, and
test version for LDCT and PLT.
Fully adjusted model: minimally adjusted model 1 adjustments for history of cerebrovascular and cardiovascular disease, history of
hypertension, history of diabetes mellitus, current smoking, baseline systolic and diastolic blood pressure, high-density lipoprotein
and low-density lipoprotein cholesterol, triglycerides, body mass index, and estimated glomerular filtration rate.
aProbability values were calculated using the interaction term of time and log-transformed NT-proBNP levels.
LDCT 5 Letter-Digit Coding Test; NT-proBNP 5 N-terminal pro–brain natriuretic peptide; PLTd 5 Picture-Word Learning Test,
delayed; PLTi 5 Picture-Word Learning Test, immediate.
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preload.24 Our results showed that higher NT-proBNP
levels were associated with higher systolic blood pressure.
Initially, higher systolic blood pressure might increase the
ventricular stress of cardiomyocytes and therefore cause
an increased release of NT-proBNP. In case of chronic
ventricular stress, this might further proceed to reduced
cardiac function and heart failure. Subsequently, cardiac
output will be reduced and blood pressure will be lower.9
Different explanations can be proposed for the
observed association of NT-proBNP with cognitive
decline. First, NT-proBNP and cognitive decline are
highly likely to reflect underlying cardiovascular damage
and therefore stem from common causes. Previous stud-
ies have shown that NT-proBNP levels have a prognostic
value for the occurrence of cardiovascular events, such as
myocardial infarction, atrial fibrillation, coronary heart
disease, unstable angina, stroke, and TIA.12,15,25,26 This
has also been demonstrated in subjects with elevated NT-
proBNP levels, but without clinical heart failure.27 Fur-
thermore, NT-proBNP levels provide predictive informa-
tion for use in risk stratification in nonfatal cardiac
events, stroke, and mortality in a range of populations
including patients with diabetes.26,28–30 These cardiovas-
cular and metabolic diseases are closely linked to cogni-
tive dysfunction and dementia.18,19 This is in line with
the finding that high NT-proBNP levels are associated
with an increased prevalence of cardiovascular diseases
and risk factors in the population under study. However,
when adjusting and stratifying our analyses for cardiovas-
cular diseases and risk factors, our results did not appre-
ciably alter. Furthermore, excluding participants with
incident myocardial infarction, stroke, and/or TIA
showed the same results. Nevertheless, we cannot rule
out the possibility that unmeasured cardiovascular risk
factors resulted in both increased NT-proBNP and cogni-
tive decline. Second, impaired cardiac function may acti-
vate the renin–angiotensin system, which in turn has
been associated with cognitive decline.31 In line with this
evidence, observational studies have suggested that sub-
jects receiving angiotensin receptor blockers may have a
lower risk of developing dementia.32,33 Because only a
small number of participants used angiotensin receptor
blockers in the population under study (n< 100), we
could not further investigate this issue. Third, because
natriuretic peptides have first been identified in porcine
brain extract, one could hypothesize that NT-proBNP
FIGURE 1: Association of N-terminal pro–brain natriuretic peptide (NT-proBNP) with cognitive decline during follow-up. Data
represent mean score (95% confidence interval) of each cognitive test during follow-up, in each group of NT-proBNP. Because the
time point of the measurement at the end of the study varied between 36 and 48 months, the mean of these time points (42
months) is reported. Probability values were calculated using the interaction term of time and log-transformed NT-proBNP levels.
Adjustments were made for age, sex, country, education, ApoE genotype, treatment group, and test version where appropriate. CI,
confidence interval.
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could have a direct effect in the brain. Although there is
evidence that natriuretic peptides have receptors on endo-
thelial cells, it is to our knowledge unknown whether
NT-proBNP alters cerebral autoregulation.7,34 A fourth
explanation might be that high NT-proBNP levels in
subjects without advanced stages of heart failure indicate
suboptimal left ventricular functioning with subsequent
decreased cardiac output and cerebral hypoperfusion.9,16
Cerebral hypoperfusion, which impairs the delivery of
oxygen and nutrients to the brain, has been associated
with cognitive dysfunction and dementia.7–9 Although
this explanation seems plausible, there is a need for
interventional studies investigating the influence of
improvement in cardiac function with its subsequent
influence on cerebral perfusion, and eventually the pre-
vention of cognitive decline in old age.
The present study found that participants with pre-
vious stroke and/or TIA had a less steep decline on the
Letter-Digit Coding Test, which is unexpected and not
in line with previous literature. Nevertheless, no differen-
ces were observed for participants with previous stroke
and/or TIA on the Stroop test, immediate Picture-Word
Learning Test, and delayed Picture Word Learning Test.
Furthermore, as there was no significant association
between NT-proBNP levels and history of stroke and/or
TIA, we could not explain this association from a
FIGURE 2: Association of N-terminal pro–brain natriuretic peptide (NT-proBNP) with cognitive decline during follow-up, strati-
fied by cardiovascular diseases and risk factors. Data represent mean annual change (95% confidence interval [CI]) per 1ng/l
increase in log-transformed NT-proBNP for each cognitive test, stratified by cardiovascular diseases. Probability values were calcu-
lated using the interaction term of cardiovascular disease and log-transformed NT-proBNP level and represent the statistical differ-
ence in annual change in cognitive function between participants with and without cardiovascular disease or risk factors.
Adjustments were made for age, sex, country, education, ApoE genotype, treatment group, and test version where appropriate.
TIA 5 transient ischemic attack.
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biologically perspective. Therefore, we believe that the
most likely explanation for this finding is chance.
Major strengths of this study include the large sample
size of >5,000 older participants and the repeated use of
an extended standardized cognitive test battery to assess
cognitive function over a mean follow-up period of 3.2
years. Furthermore, in contrast to previous studies, partici-
pants with NYHA functional class III/IV were excluded,
which gave us the opportunity to investigate NT-proBNP
in relation to cognitive function and decline in participants
without advanced stages of clinical heart failure. However,
a limitation of the study is that there was no information
on the incidence of dementia during follow-up, nor was
there information on cardiac functioning or NYHA class I
or II. We might therefore have included participants with
(beginning stages of) clinical heart failure, without ever
being diagnosed with this condition. However, excluding
participants with NT-proBNP levels of 450 ng/l showed
essentially the same results. As high NT-proBNP levels
have been recognized as a predictor of heart failure, this
finding further suggests an association between NT-
proBNP and cognitive decline.35 Furthermore, our study
population consisted of older participants at risk of cardio-
vascular diseases with relatively preserved cognitive function
(MMSE 24 points), which might limit extrapolation of
our findings to a general population of older subjects.
In conclusion, higher NT-proBNP levels associate
with worse cognitive function and steeper cognitive
decline in older adults, independent of cardiovascular dis-
eases and risks. Further studies to unravel the underlying
mechanisms are warranted.
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